Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx's Late-Stage Clinical Trial Reaches New Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial Approval in China Supports Global Development Strategy for TauRx\u2019s Oral Tau Aggregation Inhibitor","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tau-Targeting Alzheimer's Treatment, HMTM, Moving Toward Regulatory Submission Based on Initial Data From TauRx's LUCIDITY trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx Announces Results from Phase 3 Alzheimer\u2019s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TauRx Announces Additional Investment of USD119 Million Following Announcement Of Phase 3 LUCIDITY Topline Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LUCIDITY Phase 3 Topline Data Presented At CTAD For HMTM - The Only Oral Anti-Tau Therapy In Late-stage Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by TauRx Therapeutics

    Menu

    TauRx Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TauRx Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial

              Details:

              TauRx's lead product candidate TRx0237 (hydromethylthionine), a tau protein inhibitor. Currently, it is being evaluated in the Phase III clinical trial studies for the treatment of Alzheimer's disease.

              Lead Product(s): Hydromethylthionine

              Therapeutic Area: Neurology Product Name: TRx0237

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TauRx Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LUCIDITY Phase 3 Topline Data Presented At CTAD For HMTM - The Only Oral Anti-Tau Therapy In Late-stage Development

              Details:

              TRx0237 is a small molecule drug being tested for its ability to inhibit aggregation of tau, a protein that forms neurofibrillary tangles in the brains of people with Alzheimer's and other neurodegenerative diseases.

              Lead Product(s): Hydromethylthionine

              Therapeutic Area: Neurology Product Name: TRx0237

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TauRx Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TauRx Announces Additional Investment of USD119 Million Following Announcement Of Phase 3 LUCIDITY Topline Results

              Details:

              HMTM or TRx0237 is an oral tau aggregation inhibitor, targeting this underlying pathology. TauRx’s HMTM has the potential to become the first disease-modifying therapies (DMT) targeting tau to be approved for AD.

              Lead Product(s): Hydromethylthionine

              Therapeutic Area: Neurology Product Name: TRx0237

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing November 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TauRx Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions

              Details:

              For people with early Alzheimer’s (MCI), HMTM, a potent inhibitor of Tau aggregation treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals.

              Lead Product(s): Hydromethylthionine

              Therapeutic Area: Neurology Product Name: TRx0237

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TauRx Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tau-Targeting Alzheimer's Treatment, HMTM, Moving Toward Regulatory Submission Based on Initial Data From TauRx's LUCIDITY trial

              Details:

              TauRx's lead investigative oral drug, TRx0237, has been tested in 598 people with Alzheimer's. Following our 12 month blinded phase of the study, participants have moved forward to an additional one year open label phase.

              Lead Product(s): Hydromethylthionine

              Therapeutic Area: Neurology Product Name: TRx0237

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TauRx Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TauRx's Late-Stage Clinical Trial Reaches New Milestone

              Details:

              This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM).

              Lead Product(s): Hydromethylthionine

              Therapeutic Area: Neurology Product Name: TRx0237

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TauRx Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Trial Approval in China Supports Global Development Strategy for TauRx’s Oral Tau Aggregation Inhibitor

              Details:

              IND approval was formally given on 10 March 2022 paving the way for TauRx to build on its global strategy to bring to market the first disease modifying treatment for Alzheimer’s disease targeting the tau pathology of Alzheimer’s disease (AD).

              Lead Product(s): TRx-237-801

              Therapeutic Area: Neurology Product Name: TRx-237-801

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TauRx Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia

              Details:

              Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease.

              Lead Product(s): Hydromethylthionine

              Therapeutic Area: Neurology Product Name: TRx0237

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY